Also trades as: SMSPHARMA.NS (NSE) · $vol 3M
SMSPHARMA.BO BSE
SMS Pharmaceuticals Limited
1W: -0.6%
1M: +27.7%
3M: +11.1%
YTD: +47.9%
1Y: +103.6%
3Y: +294.9%
5Y: +157.1%
₹475.80 ($4.94)
+4.20 (+0.89%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$8.9B
+13.3% ▲
5Y CAGR: +9.6%
Gross Profit
$1.7B
+20.7% ▲
5Y CAGR: -0.7%
Operating Income
$1.3B
+27.1% ▲
5Y CAGR: +6.1%
Net Income
$1.0B
+47.5% ▲
5Y CAGR: +10.3%
EPS (Diluted)
$11.15
+36.8% ▲
5Y CAGR: +8.6%
EBITDA
$1.7B
+17.9% ▲
5Y CAGR: +6.6%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $5.2B | $7.1B | $7.8B | $8.9B |
| YoY Growth | -8.2% | +1.4% | +35.9% | +10.4% | +13.3% |
| Cost of Revenue | $3.3B | $3.9B | $5.0B | $6.4B | $7.1B |
| Gross Profit | $1.8B | $1.3B | $2.1B | $1.4B | $1.7B |
| Gross Margin | 35.2% | 24.7% | 29.7% | 18.5% | 19.7% |
| R&D Expenses | $84M | $89M | $111M | $128M | $0 |
| SG&A Expenses | $84M | $94M | $658M | $403M | $436M |
| Operating Expenses | $990M | $265M | $769M | $403M | $436M |
| Operating Income | $790M | $213M | $1.3B | $1.0B | $1.3B |
| Operating Margin | 15.3% | 4.1% | 18.9% | 13.2% | 14.8% |
| Interest Expense | $189M | $219M | $235M | $185M | $231M |
| Income Before Tax | $628M | -$56M | $667M | $941M | $1.3B |
| Tax Expense | $6M | $15M | $169M | $249M | $286M |
| Net Income | $622M | -$71M | $498M | $691M | $1.0B |
| Net Margin | 12.1% | -1.4% | 7.0% | 8.8% | 11.5% |
| EPS (Diluted) | $7.35 | $-0.83 | $5.89 | $8.15 | $11.15 |
| EBITDA | $1.2B | $594M | $1.2B | $1.5B | $1.7B |
| Shares Outstanding | 85M | 85M | 85M | 85M | 91M |